D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.
Commentary|Podcasts|June 10, 2026
Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD
Author(s)Joshua Richter, MD
Fact checked by: Chris Ryan, Ashling Wahner
Joshua Richter, MD, previews some of the most anticipated multiple myeloma presentations ahead of the 2026 EHA Congress.
Advertisement
Advertisement
Welcome to OncLive On Air®! I'm your host today, Chris Ryan
Related to this article
Arlocabtagene autoleucel met the primary end point of overall response rate in the registrational phase 2 QUINTESSENTIAL trial.
Patients with triple-class–exposed relapsed/refractory multiple myeloma reported improvements in pain, fatigue, and functioning during up to 2 years of linvoseltamab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Etentamig improved ORR and PFS vs standard therapies in triple-class exposed relapsed/refractory multiple myeloma.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
Advertisement
Advertisement